Comparison of survival with somatostatin analog and chemotherapy and prognostic factors for treatment in 165 advanced neuroendocrine tumor patients with Ki-67 20% or less
dc.contributor.author | Ozaslan, Ersin | |
dc.contributor.author | Karaca, Halit | |
dc.contributor.author | Koca, Sinan | |
dc.contributor.author | Sevinc, Alper | |
dc.contributor.author | Hacioglu, Bekir | |
dc.contributor.author | Ozkan, Metin | |
dc.contributor.author | Ozcelik, Melike | |
dc.contributor.author | Duran, Ayse O. | |
dc.contributor.author | Hacibekiroglu, Ilhan | |
dc.contributor.author | Yildiz, Yasar | |
dc.contributor.author | Tanriverdi, Ozgur | |
dc.contributor.author | Menekse, Serkan | |
dc.contributor.author | Aksoy, Asude | |
dc.contributor.author | Bozkurt, Oktay | |
dc.contributor.author | Urvay, Semiha | |
dc.contributor.author | Uysal, Mukremin | |
dc.contributor.author | Demir, Hacer | |
dc.contributor.author | Ciltas, Aydin | |
dc.contributor.author | Dane, Faysal | |
dc.date.accessioned | 2019-07-27T12:10:23Z | |
dc.date.accessioned | 2019-07-28T09:44:02Z | |
dc.date.available | 2019-07-27T12:10:23Z | |
dc.date.available | 2019-07-28T09:44:02Z | |
dc.date.issued | 2017 | |
dc.identifier.issn | 0959-4973 | |
dc.identifier.issn | 1473-5741 | |
dc.identifier.uri | https://dx.doi.org/10.1097/CAD.0000000000000445 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12418/6867 | |
dc.description | WOS: 000392824000012 | en_US |
dc.description | PubMed ID: 27768606 | en_US |
dc.description.abstract | The objectives of this study were to compare progression-free survival (PFS) with somatostatin analog (SSA) versus chemotherapy (CTx) in first-line therapy and to determine the patient group in which these treatments were more effective in neuroendocrine tumors (NETs) with a Ki-67 index of 20% or less. Patients who received SSA or CTx and had unresectable locally advanced and metastatic NETs with a Ki-67 index of 20% or less were retrospectively selected from 13 centers in the Turkish database between 2000 and 2015. One hundred and sixty-five patients were enrolled. The median age was 56 years and the male-to-female ratio was 1.09. Seventy-four (45%) patients were of grade 1 NET and 91 (55%) were of grade 2. SSA was given to 104 patients, whereas 61 were treated with CTx. The objective response rate after SSA was 15.4%; another 73.1% had stable disease. The objective response rate after CTx was 36.1%, and 40.9% had stable disease (P = 0.008). The median PFS in SSA patients was 21 months (95% confidence interval: 12.4-29.6), and 8 months for CTx (95% confidence interval: 5.5-10.6) (P < 0.001). There was no significant difference between PFS of receiving SSA and CTx in pancreatic neuroendocrine tumor (PNET) patients; however, the PFS of receiving SSA was longer in non-PNET patients (P < 0.001). SSA was better treatment in advanced NET patients with a Ki-67 index of less than 5%, having a primary resected and a performance status of 0 (P < 0.05). SSA may be preferred over CTx in advanced NET patients with low-to-intermediate grade. Copyright (C) 2017 Wolters Kluwer Health, Inc. All rights reserved. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | en_US |
dc.relation.isversionof | 10.1097/CAD.0000000000000445 | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | chemotherapy | en_US |
dc.subject | Ki-67 index | en_US |
dc.subject | lanreotide | en_US |
dc.subject | neuroendocrine tumor | en_US |
dc.subject | octreotide | en_US |
dc.subject | pancreatic neuroendocrine tumor | en_US |
dc.subject | somatostatin analog | en_US |
dc.title | Comparison of survival with somatostatin analog and chemotherapy and prognostic factors for treatment in 165 advanced neuroendocrine tumor patients with Ki-67 20% or less | en_US |
dc.type | article | en_US |
dc.relation.journal | ANTI-CANCER DRUGS | en_US |
dc.contributor.department | [Ozaslan, Ersin -- Karaca, Halit -- Ozkan, Metin -- Bozkurt, Oktay] Erciyes Univ, Sch Med, Div Med Oncol, Kayseri, Turkey -- [Koca, Sinan -- Dane, Faysal] Marmara Univ, Sch Med, Div Med Oncol, Istanbul, Turkey -- [Ozcelik, Melike] Kartal Training & Res Hosp, Div Med Oncol, Istanbul, Turkey -- [Sevinc, Alper] Gaziantep Univ, Sch Med, Div Med Oncol, Gaziantep, Turkey -- [Hacioglu, Bekir -- Hacibekiroglu, Ilhan] Trakya Univ, Sch Med, Div Med Oncol, Edirne, Turkey -- [Duran, Ayse O.] Abdurrahman Yurtaslan Training & Res Hosp, Div Med Oncol, Ankara, Turkey -- [Demir, Hacer -- Ciltas, Aydin] Gazi Univ, Sch Med, Div Med Oncol, Ankara, Turkey -- [Yildiz, Yasar] Izmir Katip Calebi Univ, Sch Med, Div Med Oncol, Izmir, Turkey -- [Tanriverdi, Ozgur] Mugla Sitki Kocman Univ, Sch Med, Div Med Oncol, Mugla, Turkey -- [Menekse, Serkan] Celal Bayar Univ, Sch Med, Div Med Oncol, Manisa, Turkey -- [Aksoy, Asude] Firat Univ, Sch Med, Div Med Oncol, Elazig, Turkey -- [Urvay, Semiha] Cumhuriyet Univ, Sch Med, Div Med Oncol, Sivas, Turkey -- [Demir, Hacer] Afyon Kocatepe Univ, Sch Med, Div Med Oncol, Afyon, Turkey | en_US |
dc.contributor.authorID | aksoy, asude -- 0000-0002-5609-9658 | en_US |
dc.identifier.volume | 28 | en_US |
dc.identifier.issue | 2 | en_US |
dc.identifier.endpage | 229 | en_US |
dc.identifier.startpage | 222 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |
This item appears in the following Collection(s)
-
Makale Koleksiyonu [5200]
Article Collection -
Makale Koleksiyonu [5745]
Article Collection -
Öksüz Yayınlar Koleksiyonu - WoS [6162]